Androgens and transforming growth factor beta modulate the growth response to epidermal growth factor in human prostatic tumor cells (LNCaP).

Treatment of LNCaP human prostatic cancer cells with 0.1 nM of the synthetic androgen, R1881, resulted in a three-fold stimulation of growth in 6 days. Of several growth factors tested (epidermal growth factor (EGF), platelet-derived growth factor, insulin-like growth factor, and insulin) only EGF (1 ng/ml) stimulated cell growth (two-fold). This stimulatory effect of EGF was inhibited for approximately 70% by 0.02 ng transforming growth factor beta (TGF beta)/ml. EGF (1 ng/ml) acted synergistically with R1881 (0.1 nM) on LNCaP cells to induce cell proliferation (seven-fold increase in cell growth). The synergistic effect of androgen and EGF was inhibited by TGF beta (0.05 ng/ml). human prostatic LNCaP cells are sensitive to EGF. Androgen increases and TGF beta decreases the growth response to EGF. This effect of TGF beta on an androgen-responsive system has not been observed before.